Switch View
© PR Newswire
02.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the federal securities laws....
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Centene Corporation Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CNC
News Preview
LOS ANGELES, Sept. 2, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Centene Corporation ("Centene" or "the Company") (NYSE: CNC) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.09.2025
ISIN: US60770K1079
Moderna, Inc
MRNA
LISTED
NASDAQ
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
News Preview
CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM), which will be held September 2-6, 2025 in Kyoto, Japan, at the Kyoto Internation...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
02.09.2025
ISIN: FR0010331421
Innate Pharma SA
IPH
LISTED
EURONEXT
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025
News Preview
Regulatory News:
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as wel...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
02.09.2025
ISIN: DK0060448595
Coloplast A/S
COLO B
LISTED
CPH
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4
News Preview
The new 5-year strategy, Impact4, will be presented today at the company’s Capital Markets Day 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: DK0060448595
Coloplast A/S
COLO B
LISTED
CPH
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030
News Preview
...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 1, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.09.2025
ISIN: CA0909741062
BioNxt Solutions Inc.
BNXT
LISTED
CSE
Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
News Preview
VANCOUVER, BC / ACCESS Newswire / September 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:XPHYF)(FSE:4XT) is pleased to announce the receipt of the Semaglutide active pharmaceutical ingredient (API), enabling the initiation of laboratory-scale formulation and testing of the Company's oral dissol...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ISIN: US98887Q1040
Zai Lab Limited
ZLAB
LISTED
NASDAQ
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
“Today’s approval of TIVDAK marks an important milestone for Za...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: VGG111961055
Biohaven Ltd.
BHVN
LISTED
NYSE
BHVN Deadline: BHVN Investors with Losses in Excess of $100K Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 1, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the "Class Period"), of the important September 12, 2025 lead plaintiff deadline....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.09.2025
ISIN: US91678A1079
Upstream Bio, Inc.
UPB
LISTED
NASDAQ
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
News Preview
Upstream Bio to Host Conference Call/Webcast to Report Top-Line Data from Phase 2 VIBRANT Trial of Verekitug in Patients with CRSwNP...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Sept. 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
01.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LFMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that LifeMD, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
NEW YORK, Sept. 1, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against LifeMD, Inc. ("LifeMD" or "the Company") (NASDAQ: LFMD) and certain of its officers....
Themefolio
Profiler
Peergroup
© ActuNews
01.09.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion bevestigt de vooruitgang van de onderhandelingen over haar strategie voor de diversificatie van de kasmiddelen; closing van de transactie wordt vóór 25 september 2025 verwacht
News Preview
Leuven, BELGIË – 1 september 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, kondigt aan dat de onderhandelingen met Atlas Special Opportunities over de financieringsovereenkomst constructief verlopen. De vennootschap verwacht de transactie vóó...
Themefolio
Profiler
Peergroup
© ActuNews
01.09.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion confirme l'avancée des négociations relatives à sa stratégie de diversification de sa trésorerie ; un closing de l'opération est envisagé avant le 25 septembre 2025
News Preview
Louvain, Belgique, 1er septembre 2025, 18h00, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce que les négociations avec Atlas Special Opportunities autour de la convention de financement avancent de manière constructive. La société envisage un closing de l'o...
Themefolio
Profiler
Peergroup
© ActuNews
01.09.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion confirms progress in negotiations related to its treasury diversification strategy; closing of the transaction expected before September 25, 2025
News Preview
Leuven, BELGIUM – September 1, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that negotiations with Atlas Special Opportunities regarding the financing agreement are progressing constructively. The company expects to close the transaction before September...
Themefolio
Profiler
Peergroup
© ActuNews
01.09.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – September 1, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on August 28, 2025, from A...
Themefolio
Profiler
Peergroup
© ActuNews
01.09.2025
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 1 september 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transp...
Themefolio
Profiler
Peergroup
© EQS Newswire
01.09.2025
ISIN: CH0012627250
HBM Healthcare Investments AG
HBMN
LISTED
SIX
Key Figures
31.08.2025
News Preview
HBM Healthcare Investments AG
/ Key word(s): Monthly Figures
Key Figures
31.08.2025
01.09.2025 / 17:47 CET/CEST
in CHF
Performance in %
31.08.2025
MTD
FYTD
CYTD
NAV
240.62
3.5
1.5
......
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: US02155H2004
Altimmune Inc
ALT
LISTED
NASDAQ
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 1, 2025 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead plaintiff deadline....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.09.2025
ISIN: DK0011048619
BioPorto A/S
BIOPOR
LISTED
CPH
Grant of Warrants
News Preview
September 1, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: US8292141053
Simulations Plus Inc
SLP
LISTED
NASDAQ
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
News Preview
NEW YORK, Sept. 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.09.2025
ISIN: FR0000121667
EssilorLuxottica SA
EL
LISTED
EURONEXT
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2025
News Preview
Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
ANRO Deadline: ANRO Investors with Losses in Excess of $100K Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 1, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the "IPO"); and/or (ii) securities between February 2, 2024 and October 22, 2...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLCLEI: 5493003YBCY4W1IMJU04NET ASSET VALUEThe estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for Worldwide Healthcare Trust PLC at the close of business on 29 August 2025 was 355.73p (cum income). ...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: SE0009807266
Integrum AB (B)
INTEG B
LISTED
STO
Integrum AB: Correction of Figures in Interim Report for the First Quarter 2025/26
News Preview
MÖLNDAL, Sweden, Sept. 1, 2025 /PRNewswire/ -- When publishing the interim report for the company, it was discovered that some of the total sums in the income statement show the wrong amounts. The sum of Net Sales and Work Performed by Own Use and Activated has mistakenly included Other operating income. Moreover, Other operating expenses was sum...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse : Yves Jacob nommé responsable R&D France de Sanofi à compter du 1er septembre
News Preview
Yves Jacob nommé responsable R&D France de Sanofi à compter du 1er septembre...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: SE0000135485
RaySearch Laboratories AB (publ)
RAY B
LISTED
STO
RaySearch launches RayIntelligence® v2025
News Preview
STOCKHOLM, Sept. 1, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) today announced the release of RayIntelligence®* v2025, a major update to its oncology analytics system designed to transform clinical data into actionable insights. With new tools for building customized dashboards and deeper integration across RaySearch's product portfoli...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.09.2025
ISIN: DK0061155009
Pharma Equity Group A/S
PEG
LISTED
CPH
Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.09.2025
ISIN: CA13765U2002
Cannara Biotech Inc.
LOVE
LISTED
TSX
Cannara Announces Grant of Options and RSUs
News Preview
Cannara grants stock options & RSUs, marking 5 years of growth and reinforcing long-term alignment of employees, directors, and investors...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Total Voting Rights
News Preview
01 September 2025 LEI: 5493003YBCY4W1IMJU04 Worldwide Healthcare Trust PLC Voting Rights and Capital In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, Worldwide Healthcare Trust PLC announces the following: As at 31 August 2025, Worldwide Healthcare Trust PLC's capital consists of...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
01.09.2025
ISIN: GB00BYX3WZ24
Hemogenyx Pharmaceuticals plc
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.Issu...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: SE0022419784
Sectra AB
SECT_B
LISTED
STO
University medical center in Germany expands use of Sectra's solution with AI service--accelerates adoption of AI for enhanced efficiency and patient care
News Preview
LINKÖPING, Sweden, Sept. 1, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that Universitätsmedizin Göttingen (UMG Göttingen) in Germany will expand its enterprise imaging solution to include Sectra's AI service, Sectra Amplifier Service. The AI service, operated within Microsoft Azu...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.09.2025
ISIN: SE0006887451
Corline Biomedical AB
CLBIO
LISTED
STO
Kardiums Globe-kateter med CHS™-coatning erhåller FDA-godkännande
News Preview
FDA meddelar idag via sin hemsida att de godkänt kanadensiska Kardiums PMA-ansökan för Globe® Pulsed Field System (godkännande #240044). Det innebär att en CHS™-coatad produkt för första gången någonsin godkänns för att säljas på världens största medicinteknikmarknad, den amerikanska. Se mer på: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: SE0009807266
Integrum AB (B)
INTEG B
LISTED
STO
Integrum AB: Stronger positioning paves the way for continued growth
News Preview
MÖLNDAL, Sweden, Sept. 1, 2025 /PRNewswire/ --
First quarter 2025/26 (May - July)
Net sales amounted to SEK 23.8 (18.5) million.Operating loss totalled SEK 12.4 (12.0) million.Profit/loss after tax amounted to SEK -10.0 (-9.4) million.Earnings per share amounted to SEK -0.47 (-0.49).Cash flow totalled SEK -12.4 (29.3) million.Significant events...
Themefolio
Profiler
Peergroup
© EQS Newswire
01.09.2025
ISIN: CH0013396012
SKAN Group AG
SKAN
LISTED
SIX
Jonas Greutert übernimmt per 1. Januar 2025 von Thomas Huber
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR
CEO-Wechsel bei der SKAN Group: Jonas Greutert übernimmt per 1. Januar 2025 von Thomas Huber
Allschwil, 1. September 2025 – Die SKAN Gruppe gibt bekannt, dass der Verwaltungsrat die strategische Nachfolgeplanung für die CEO-Position mit der Ernennung von Jonas Greutert per 1. Januar 2026 abgeschlossen hat. Der ......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.09.2025
ISIN: CH0013396012
SKAN Group AG
SKAN
LISTED
SIX
Jonas Greutert to succeed Thomas Huber effective January 1, 2026
News Preview
Ad hoc announcement pursuant to Art. 53 LR
CEO transition at SKAN Group: Jonas Greutert to succeed Thomas Huber effective January 1, 2026
Allschwil, September 1, 2025 – SKAN Group announces that the Board of Directors completed the strategic succession planning process for the CEO position with the appointment of Jonas Greutert as of January 1, 2......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.09.2025
ISIN: CH0478634105
Aevis Victoria SA
AEVS
LISTED
SIX
AEVIS VICTORIA SA (AEVS.SW) – Swiss Medical Network – Umsatzwachstum von über 20% im ersten Halbjahr 2025 in einem anspruchsvollen Umfeld
News Preview
AEVIS VICTORIA SA
/ Schlagwort(e): Halbjahresergebnis
AEVIS VICTORIA SA (AEVS.SW) – Swiss Medical Network – Umsatzwachstum von über 20% im ersten Halbjahr 2025 in einem anspruchsvollen Umfeld
01.09.2025 / 07:00 CET/CEST
Pressemitteilung
Fribourg, 1. September 2025
AEVIS VICTORIA SA (AEVS.SW) – Swiss Medical Network –......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.09.2025
ISIN: CH0478634105
Aevis Victoria SA
AEVS
LISTED
SIX
AEVIS VICTORIA SA (AEVS.SW) – Swiss Medical Network – Revenue increased by more than 20% in the first half of 2025 despite challenging conditions
News Preview
AEVIS VICTORIA SA
/ Key word(s): Half Year Results
AEVIS VICTORIA SA (AEVS.SW) – Swiss Medical Network – Revenue increased by more than 20% in the first half of 2025 despite challenging conditions
01.09.2025 / 07:00 CET/CEST
Press release
Fribourg, 1 September 2025
AEVIS VICTORIA SA (AEVS.SW) – Swiss Medical Network......
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ISIN: US00287Y1091
AbbVie Inc
ABBV
LISTED
EURONEXT
AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work
News Preview
SINGAPORE, Sept. 1, 2025 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture, has selected AbbVie for the 2025 Best Workplaces in Asia™ List, ranking the company No. 7 up from No. 8 last year.
This year'...
Themefolio
Profiler
Peergroup
© PR Newswire
31.08.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
CNC Deadline: CNC Investors with Losses in Excess of $100K Have Opportunity to Lead Centene Corporation Securities Fraud Lawsuit
News Preview
NEW YORK, Aug. 31, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (...
Themefolio
Profiler
Peergroup
© PR Newswire
31.08.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump
News Preview
MADRID, Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 years, when compared to standard care, routine use of Impella CP® in patie...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.08.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
News Preview
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology...
Themefolio
Profiler
Peergroup
© PR Newswire
31.08.2025
ISIN: US81663L2007
GeneDx Holdings Corp
WGS
LISTED
NASDAQ
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
News Preview
NEW YORK, Aug. 31, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.08.2025
ISIN: US89157D1054
Tourmaline Bio Inc
TALS
LISTED
NASDAQ
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
News Preview
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.08.2025
ISIN: US87990A1060
Tenaya Therapeutics Inc
TNYA
LISTED
NASDAQ
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
News Preview
Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants...
Themefolio
Profiler
Peergroup
© BusinessWire
31.08.2025
ISIN: US02043Q1076
Alnylam Pharmaceuticals Inc
ALNY
LISTED
NASDAQ
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.08.2025
ISIN: DK0062498333
Novo Nordisk A/S
NOVO B
LISTED
CPH
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
News Preview
Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy® (semaglutide 2.4 mg) c...
Themefolio
Profiler
Peergroup
© BusinessWire
30.08.2025
ISIN: US02043Q1076
Alnylam Pharmaceuticals Inc
ALNY
LISTED
NASDAQ
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program,...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
News Preview
Basel, 30 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ability of zilebesiran, a RNAi therapeutic, to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension. This decisio...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension
News Preview
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM...
Themefolio
Profiler
Peergroup
© BusinessWire
30.08.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
News Preview
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results evaluating VERQUVO® (vericiguat) in adult patients with stable chronic heart failure and reduced ejection fraction (HFrEF). The Phase 3 VICTOR trial comparing the efficacy of VERQUVO to placebo in patients with HFrEF without a recent worsening heart failu...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
News Preview
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol...
Themefolio
Profiler
Peergroup
© PR Newswire
30.08.2025
ISIN: US29261A1007
Encompass Health Corp
EHC
LISTED
NYSE
EHC Investors Have Opportunity to Lead Encompass Health Corporation Securities Fraud Lawsuit
News Preview
NEW YORK, Aug. 29, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Encompass Health Corporation (NYSE: EHC) resulti...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
ISIN: US30161Q1040
Exelixis Inc
EXEL
LISTED
NASDAQ
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company’s drug discovery, translational research, product development and medical affairs activities.
"Dana has been an integral part of the Ex...
Themefolio
Profiler
Peergroup
© Newsfile
29.08.2025
ISIN: CA26929F1099
Sharp Therapeutics Corp.
SHRX
LISTED
TSX
Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB
News Preview
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its condensed interim consolidated financial statements for the three and six months ended June 30, 2025, and related management discussion and analysi...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Semler Scientific, Inc. (“Semler” or “the Company”) (NASDAQ: SMLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
ISIN: CA1380357048
Canopy Growth Corp
CGC
LISTED
NASDAQ
Canopy Growth Establishes New US$200 Million At-The-Market Program to Strengthen the Company’s Financial Position
News Preview
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that the Company has established a new at-the-market equity program (the “ATM Program”) that allows Canopy Growth to issue and sell up to US$200 mil...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
ISIN: US0070021086
Adicet Bio Inc
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 29, 2025.
Two individuals were hired by Adicet in August 2025. In the aggregate, Adicet granted new hires non-qualifi...
Themefolio
Profiler
Peergroup
© Newsfile
29.08.2025
ISIN: CA88337V1004
Theralase Technologies Inc.
TLT
LISTED
TSX
Theralase(R) Extends Warrants
News Preview
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
